Diagnostics
The technology is intended for those at high risk of stroke, such as stroke survivors and those diagnosed with transient ischemic attack.
Hi, what are you looking for?
TMG360 News
BioTechnology
Cancer is not an easy target. It consists of a disease spectrum that ranges from high lethality that is spreading rapidly to locally confined...
Artificial Intelligence
Recent advancements in biotechnology have immense potential to help address many global problems; climate change, an aging society, food security, energy security, and infectious...
Consumer Empowered Health
The company has struck partnerships with properties owned by Cedars-Sinai, BayCare and others, and is looking to build out some healthcare-specific features, such as...
Clinical Trials
The REVEALPLAQUE trial is planned to enroll 250 patients with stable coronary artery disease from approximately 15 sites across the U.S. and Japan.
Diagnostics
The Penn State research group is confident that the tiny levels of glucose found in sweat can provide a meaningful correlation with the amount...
Digital Health
The platform connects families and their children with pediatric telehealth services and aims to enable equitable access to quality care for all Canadian children.
BioTechnology
The study’s primary endpoint was long-term freedom from arrhythmia recurrence, with a mean follow-up time of 5.5 years. AV(N)RTs cause abnormally fast heartbeats and...
Artificial Intelligence
The platform includes continuous glucose monitors (CGMs), fitness watches, comprehensive blood tests and the development of each member’s individualized Whole Body Digital Twin, along...
Diagnostics
SyncThink, a neurotechnology company and developer of the EYE-SYNC technology, has received clearance from the Food and Drug Administration (FDA) for the EYE-SYNC technology...
Artificial Intelligence
Artificial Intelligence
